These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 29156195)

  • 21. [Acute leukemia in adults].
    Eigendorff E; Hochhaus A
    Pathologe; 2015 Sep; 36(5):503-17; quiz 518-9. PubMed ID: 26314268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Minimal residual disease markers before and after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
    Dominietto A
    Curr Opin Hematol; 2011 Nov; 18(6):381-7. PubMed ID: 21986564
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Consolidation chemotherapy prior to hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission.
    Appelbaum FR
    Best Pract Res Clin Haematol; 2016 Dec; 29(4):365-371. PubMed ID: 27890261
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Post-remissional and pre-transplant role of minimal residual disease detected by WT1 in acute myeloid leukemia: A retrospective cohort study.
    Frairia C; Aydin S; Audisio E; Riera L; Aliberti S; Allione B; Busca A; D'Ardia S; Dellacasa CM; Demurtas A; Evangelista A; Ciccone G; Francia di Celle P; Nicolino B; Stacchini A; Marmont F; Vitolo U
    Leuk Res; 2017 Oct; 61():10-17. PubMed ID: 28846953
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.
    Döhner H; Estey E; Grimwade D; Amadori S; Appelbaum FR; Büchner T; Dombret H; Ebert BL; Fenaux P; Larson RA; Levine RL; Lo-Coco F; Naoe T; Niederwieser D; Ossenkoppele GJ; Sanz M; Sierra J; Tallman MS; Tien HF; Wei AH; Löwenberg B; Bloomfield CD
    Blood; 2017 Jan; 129(4):424-447. PubMed ID: 27895058
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute myeloid leukemia in children: Current status and future directions.
    Taga T; Tomizawa D; Takahashi H; Adachi S
    Pediatr Int; 2016 Feb; 58(2):71-80. PubMed ID: 26645706
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Can we incorporate MRD assessment into clinical practice in AML?
    Ossenkoppele G; Schuurhuis GJ; van de Loosdrecht A; Cloos J
    Best Pract Res Clin Haematol; 2019 Jun; 32(2):186-191. PubMed ID: 31204000
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia.
    Maurillo L; Buccisano F; Del Principe MI; Del Poeta G; Spagnoli A; Panetta P; Ammatuna E; Neri B; Ottaviani L; Sarlo C; Venditti D; Quaresima M; Cerretti R; Rizzo M; de Fabritiis P; Lo Coco F; Arcese W; Amadori S; Venditti A
    J Clin Oncol; 2008 Oct; 26(30):4944-51. PubMed ID: 18606980
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incorporating hematopoietic cell transplantation (HCT) into the management of adults aged under 60 years with acute myeloid leukemia (AML).
    Appelbaum FR
    Best Pract Res Clin Haematol; 2008 Mar; 21(1):85-92. PubMed ID: 18342816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute myeloid leukemia.
    Stone RM; O'Donnell MR; Sekeres MA
    Hematology Am Soc Hematol Educ Program; 2004; ():98-117. PubMed ID: 15561679
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia.
    Candoni A; De Marchi F; Zanini F; Zannier ME; Simeone E; Toffoletti E; Chiarvesio A; Cerno M; Filì C; Patriarca F; Fanin R
    Exp Hematol; 2017 May; 49():25-33. PubMed ID: 28159598
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Should minimal residual disease guide therapy in AML?
    Paietta E
    Best Pract Res Clin Haematol; 2015; 28(2-3):98-105. PubMed ID: 26590765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia.
    Percival MM; Estey EH
    Cancer; 2019 Sep; 125(18):3121-3130. PubMed ID: 31291012
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies.
    Díez-Campelo M; Pérez-Simón JA; Pérez J; Alcoceba M; Richtmon J; Vidriales B; San Miguel J
    Am J Hematol; 2009 Mar; 84(3):149-52. PubMed ID: 19123459
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted and cytotoxic therapies as maintenance treatment for non-transplant eligible patients with acute myeloid leukemia.
    Patel SA; Litzow MR; Cerny J
    Blood Rev; 2021 Nov; 50():100863. PubMed ID: 34210571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging treatments in acute myeloid leukemia: current standards and unmet challenges.
    Percival ME; Estey E
    Clin Adv Hematol Oncol; 2017 Aug; 15(8):632-642. PubMed ID: 28949951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Should the presence of minimal residual disease (MRD) in morphologic complete remission alter post-remission strategy in AML?
    Stone RM
    Best Pract Res Clin Haematol; 2011 Dec; 24(4):509-14. PubMed ID: 22127313
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.
    Chen X; Xie H; Wood BL; Walter RB; Pagel JM; Becker PS; Sandhu VK; Abkowitz JL; Appelbaum FR; Estey EH
    J Clin Oncol; 2015 Apr; 33(11):1258-64. PubMed ID: 25732155
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Can Minimal Residual Disease Determination in Acute Myeloid Leukemia Be Used in Clinical Practice?
    Luskin MR; Stone RM
    J Oncol Pract; 2017 Aug; 13(8):471-480. PubMed ID: 28796964
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of Wilms' tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML.
    Duléry R; Nibourel O; Gauthier J; Elsermans V; Behal H; Coiteux V; Magro L; Renneville A; Marceau A; Boyer T; Quesnel B; Preudhomme C; Duhamel A; Yakoub-Agha I
    Bone Marrow Transplant; 2017 Apr; 52(4):539-543. PubMed ID: 28067876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.